SecBot SecBot

PROK drug pipeline

PROKIDNEY CORP. · 1 rated drug
$1.04
−0.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.

REACT rilparencel Updated Oct 25

What to watch

The next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.

Bull case
  • Phase 2 REGEN-007 Group 1 showed a 78% improvement in annual eGFR decline (4.6 mL/min/1.73m², p<0.001), with a subgroup matching Phase 3 criteria showing 85% improvement, per July 2025 top-line results.
  • FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation and agreed to an accelerated approval pathway using eGFR slope as a surrogate endpoint, potentially enabling approval from a single Phase 3 trial.
  • PROACT 1 enrollment completed mid-2026 with topline results expected Q2 2027; cash of $181.6M (as of June 30, 2026) funds operations into mid-2027, covering the readout.
Bear case
  • Phase 2 REGEN-007 was small (n=24 in the lead Group 1) and open-label; one of two dosing groups (Group 2) missed statistical significance, raising questions about robustness.
  • Autologous cell therapy is complex and expensive to manufacture at scale since each dose is personalized from the patient's own kidney biopsy.
  • Director Brian Pereira sold ~$715K worth of shares in August 2026 at ~$1.42, according to SEC Form 4 filings.